Mpox vaccine trial for babies launches in congo: could half a dose be enough?
NCT ID NCT06844487
First seen May 03, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tests the safety and immune response of the MVA-BN mpox vaccine in 344 infants and children aged 4 to 24 months in the Democratic Republic of the Congo. Half of the children receive a full dose and half receive a half dose, both given as two shots 28 days apart. The goal is to find the best dose to protect young children from mpox, who are at high risk in this region.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boende Hôpital Général de Référence, Boende
Boende, La Tshuapa, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.